PDCD1 and melanoma: In contrast, a more recent study suggested a negative role of PD-1+ sEVs in antitumour immunity, as a higher level of circulating PD-1+ sEVs in melanoma patients was significantly correlated with a poorer clinical response to immunotherapy and survival rate, but the underlying mechanism was not elucidated30.